• 1.

    Parikh SV, et al.. Update on lupus nephritis: Core curriculum 2020. Am J Kidney Dis 2020; 76:265281. doi: 10.1053/j.ajkd.2019.10.017

  • 2.

    Furie R, et al.. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:11171128. doi: 0.1056/NEJMoa2001180

  • 3.

    Atisha-Fregoso Y, et al.. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol [published online ahead of print August 4, 2020]. doi: 10.1002/art.41466; https://onlinelibrary.wiley.com/doi/10.1002/art.41466

    • Search Google Scholar
    • Export Citation
  • 4.

    Furie R, et al.. A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis (abstract). Arthritis Rheumatol 2019; 71 (Suppl 10):939. https://acrabstracts.org/abstract/a-phase-ii-randomized-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-obinutuzumab-or-placebo-in-combination-with-mycophenolate-mofetil-in-patients-with-active-class-iii/

    • Search Google Scholar
    • Export Citation
  • 5.

    Rovin BH, et al.. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 2019; 95:219231. doi: 10.1016/j.kint.2018.08.025

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Arriens C, et al.. AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis. Aurinia. June 5, 2020. https://d1io3yog0oux5.cloudfront.net/_b9287cb2b9b32ac3fbb5d08113841567/auriniapharma/db/246/1327/pdf/EULAR+2020+AURORA_Presentation+Deck+05Jun2020.pdf

    • Search Google Scholar
    • Export Citation
  • 7.

    Aurinia. FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis. January 22, 2021. https://ir.auriniapharma.com/press-releases/detail/210

    • Search Google Scholar
    • Export Citation
  • 8.

    MetroHealth Medical Center. Pentoxifylline in Lupus Nephritis (Pentoxifylline). ClinicalTrials.gov: NCT03859570. https://clinicaltrials.gov/ct2/show/NCT03859570

    • Search Google Scholar
    • Export Citation
  • 9.

    BeiGene. Zanubrutinib in Participants with Active Proliferative Lupus Nephritis. ClinicalTrials.gov: NCT04643470. https://clinicaltrials.gov/ct2/show/NCT04643470

    • Search Google Scholar
    • Export Citation
  • 10.

    Janssen Research & Development, LLC. A Study of Guselkumab in Participants with Active Lupus Nephritis (ORCHID-LN). ClinicalTrials.gov: NCT04376827. https://clinicaltrials.gov/ct2/show/NCT04376827

    • Search Google Scholar
    • Export Citation

2021 and Beyond—Lupus Nephritis

  • 1 Marco Bonilla, MD, is a nephrology fellow at Northwell Health, Great Neck, NY. Kenar D. Jhaveri, MD, FASN, is a professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, and is editor-in-chief of ASN Kidney News.
Restricted access

Lupus nephritis is a serious end organ manifestation of systemic lupus erythematosus (SLE). Regardless of the remarkable advances in the knowledge and understanding of lupus nephritis pathophysiology, it remains a weighty source of morbidity and mortality, and 10% to 30% of affected patients progress to end-stage kidney disease within 10 years of being diagnosed with SLE (1).

Therapy for lupus nephritis has continued to evolve, from the use of cyclophosphamide, azathioprine, and steroids developed in the 1970s–1980s to the use of mycophenolate, tacrolimus, cyclosporine, and rituximab in the 2000s (Figure 1). Given the significant adverse effects

Save